SIRT5 and Parkinson disease: In support of such a hypothesis, Sirt5, in particular, has been reported to act as a neuroprotective agent against motor deficit and dopaminergic degeneration in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced mouse model of Parkinson’s disease [23].